Agile Therapeutics’s Return On Capital Employed Insights
Benzinga Pro data, Agile Therapeutics (NASDAQ:AGRX) reported Q4 sales of $1.51 million. Earnings fell to a loss of $23.36 million, resulting in a 39.26% decrease from last quarter.
Preview: Agile Therapeutics’s Earnings
Agile Therapeutics (NASDAQ:AGRX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-30. Here's what investors need to know before the announcement.
Analysts estimate that Agile Therapeutics will report an earnings per share (EPS) of $-0.15.
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers
Epizyme (NASDAQ:EPZM) shares increased by 7.3% to $1.32 during Tuesday's after-market session. Epizyme's trading volume hit 240.6K shares by close, accounting for 10.7% of its average volume over the last 100 days. The company's market cap stands at $140.0 million.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
Enveric Biosciences (NASDAQ:ENVB) stock rose 6.8% to $0.64 during Friday's after-market session. The market value of their outstanding shares is at $20.8 million.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Agile Therapeutics CEO Comments On New Gov’t. Guidance Reinforcing Requirement To Cover Contraceptives Determined To Be Medically Appropriate For No Cost
On January 10, 2022, the tri-agencies, Department of Labor (DOL), Health and Human Services (HHS) and Treasury issued new guidance that supports women’s access to U.S. Food and Drug Administration (FDA) approved
Agile Therapeutics, Afaxys Report Partnership To Expand Access To Twirla Transdermal System, No Terms Disclosed
Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, today announced a new alliance with Afaxys Pharma, LLC to promote Twirla® (levonorgestrel and ethinyl estradiol) transdermal